FDA still vague over US biosimilars pathway as Abbott ‘pleads the Fifth’
This article was originally published in Scrip
For a law that is supposed to open the door to cheaper versions of branded biologic medicines, the US biosimilars legislation is turning out to be surprisingly vague in a number of respects, to the extent that it could undermine confidence in the new biosimilar approval pathway.
You may also be interested in...
Health activists are stepping up the pressure on COVID-19 vaccine companies to share their IP and reveal their costs, while the European Medicines Agency has published regulatory guidance advising vaccine developers to aim for a point estimate of efficacy of at least 50%.
The EU has ambitious plans for dealing with future health crises, bolstering needs-led innovation, improving access to medicines, and tackling drug shortages.
In its latest communication to medical product companies, the DHSC says the biggest potential cause of disruption to supplies could be failure to prepare for border controls implemented by the EU member states after the end of the Brexit transition period.